Endocrine therapy provides strong evidence that attenuation of ER (ESR1) activity can reduce breast cancer risk [7], and women with ER-positive tumor would be the most likely to benefit from these treatments [7,8]. This evidence concerns the gene ESR1 and breast carcinoma.